We’re thrilled to announce that we’ve elected Lauren Barnes to our Board of Directors. Barnes is a leading expert in healthcare product commercialization, pricing, reimbursement, market access, and managed markets for products spanning various market segments. This addition significantly bolsters our capacity to drive growth and deliver life-changing solutions for patients suffering from hematologic diseases, organ transplant rejection, and musculoskeletal defects.
“We’re delighted to welcome Lauren as the newest addition to the Ossium Board,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Lauren brings a fresh perspective to our shared passion for advancing the health, vitality, and longevity of human beings. I’m confident that her valuable insights and expertise will meaningfully help Ossium as the company continues to grow and positively impact more patients.”
Barnes’ appointment underscores our dedication to assembling a world-class Board of Directors equipped with diverse perspectives and proven expertise. Her expertise in commercialization and market access strategy at biopharmaceutical companies in various stages of development complements the expertise of the incumbent board members and will further propel us toward our goals.
At our second appearance at the Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine, Ossium CEO Kevin Caldwell presented an update on our work over the past year and outlined our vision for the future of bone marrow transplantation.
In the presentation, Kevin explained how we’re transforming the bone marrow donation process from a service into a product. With our bone marrow bank, patients have access to a high-quality, optimally-dosed, and fully-characterized graft, eliminating the months-long wait and uncertainty associated with searching for an unrelated living donor. Our vision is to enhance the existing bone marrow registry, enabling physicians to quickly search for a matched donor in a single, comprehensive registry. Ossium’s unique advantage allows physicians to expedite patients’ treatment by immediately ordering the graft once a matched donor is found. This reimagined system allows transplants to be performed in a matter of days instead of months, improving outcomes for patients whose conditions require immediate treatment.
Kevin also provided a brief update on our GVHD study and how it fits into Ossium’s goals: “Our goal is to increase the number of procedures that can be done by making them fundamentally safer.” He described how this complements Ossium’s efforts “to increase the speed, efficiency, and quality with which [bone marrow transplants] can be done by making the bone marrow itself far easier to get.”
Lastly, Kevin introduced our newest product, OssiGraft™, a viable bone matrix allograft. He explained how working with tissue from donors that have already been screened to meet organ donation and bone marrow donation requirements results in the highest quality bone graft on the market today.
Kevin Caldwell, Ossium’s CEO, Co-Founder & President, recently presented an update on our bone marrow transplant study at the 2023 Congress of the International Society for Organ Donation and Procurement. As Kevin explains in the presentation, the initiation of this clinical study is an important step toward our goal of dramatically expanding access to life-saving bone marrow transplants for blood cancer patients and enabling these procedures to be used far more broadly in the future. With our bone marrow available on-demand, patients can bypass the lengthy and uncertain process of identifying a living donor. Furthermore, patients will benefit from improved treatment outcomes due to the ability to obtain an optimized dose specific to their size and condition with lower T-cell counts.
“Our goal is to show that there’s no tradeoff between increasing the accessibility of a treatment, increasing the affordability of a treatment, and increasing the quality of a treatment. We really are shooting for all three,” summarized Kevin.
The presentation also includes an overview of Ossium’s studies of Graft-versus-Host Disease treatment and solid organ transplant tolerance induction.
Ossium Health announced today that the first patient has been treated with its newly released OssiGraft™ viable bone matrix (VBM) allograft in an ankle surgery. OssiGraft is Ossium’s viable bone matrix allograft, which is intended for use in orthopedic surgery to repair, replace, or reconstruct bone defects. This surgery represents Ossium’s transition from a clinical-stage company to a commercial company as well as its introduction to the orthopedic biologics market.
The first-in-human study of Ossium’s bone marrow (PRESERVE I) was recently featured in an article published by Healio, a major medical news source for healthcare professionals. The article includes an interview with Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, and Erin Leckrone, Vice President of Clinical Trials at the National Marrow Donor Program (NMDP)/Be The Match. In the interview, Caldwell and Leckrone outline the goals of the Ossium-NMDP/Be The Match partnership, including how the organizations plan to work together to fill unmet needs in hematopoietic cell transplantation. “We are dedicated to partnering with organizations like Ossium, who have innovative products that could potentially fill the unmet needs in transplantation,” said Leckrone. Leckrone goes on to explain how the clinical study data will be leveraged to drive the integration of Ossium’s bone marrow into the NMDP/Be The Match registry, facilitating seamless access for transplant centers in the future.
Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, recently sat down for an interview with Nasdaq’s Kristina Ayanian at their New York headquarters. In the interview, Kevin explained how Ossium is leveraging its organ donor-derived bone marrow platform to improve the accessibility and quality of leukemia treatments today and develop innovative therapies for organ rejection and orthopedic applications tomorrow.